Fibroblast growth factor 21.

Development Endocrine Fibroblast growth factor Hormone Immunity Metabolism

Journal

Differentiation; research in biological diversity
ISSN: 1432-0436
Titre abrégé: Differentiation
Pays: England
ID NLM: 0401650

Informations de publication

Date de publication:
29 Jun 2024
Historique:
received: 01 09 2023
revised: 23 06 2024
accepted: 28 06 2024
medline: 12 7 2024
pubmed: 12 7 2024
entrez: 11 7 2024
Statut: aheadofprint

Résumé

Fibroblast growth factor 21 (FGF21) belongs to the FGF19 subfamily and acts systemically, playing a key role in inter-organ crosstalk. Ranging from metabolism, reproduction, and immunity, FGF21 is a pleiotropic hormone which contributes to various physiological processes. Although most of its production across species stems from hepatic tissues, expression of FGF21 in mice has also been identified in adipose tissue, thymus, heart, pancreas, and skeletal muscle. Elevated FGF21 levels are affiliated with various diseases and conditions, such as obesity, type 2 diabetes, preeclampsia, as well as cancer. Murine knockout models are viable and show modest weight gain, while overexpression and gain-of-function models display resistance to weight gain, altered bone volume, and enhanced immunity. In addition, FGF21-based therapies are at the forefront of biopharmaceutical strategies aimed at treating metabolic dysfunction-associated steatotic liver disease.

Identifiants

pubmed: 38991938
pii: S0301-4681(24)00049-5
doi: 10.1016/j.diff.2024.100793
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100793

Informations de copyright

Copyright © 2024 International Society of Differentiation. Published by Elsevier B.V. All rights reserved.

Auteurs

Guillaume J Trusz (GJ)

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. Electronic address: gtrusz@mdanderson.org.

Classifications MeSH